小剂量HAG及地西他滨联合方案治疗老年AML患者疗效的研究

目的:研究小剂量HAG及地西他滨联合方案治疗老年急性髓系白血病患者的疗效。方法:选取2015年3月至2018年12月本院收治的老年急性髓系白血病患者134例,根据治疗方案分为CAG组及联合治疗组(HAG+Decitabine),CAG组采用CAG方案治疗,联合治疗组采用小剂量HAG及地西他滨联合方案治疗方案,治疗后评价疗效。结果:治疗1个周期后,联合治疗组总缓解率显著高于CAG组(χ^2=5.311,P=0.021)。治疗后,2组患者恶心呕吐,感染,骨髓功能抑制,出血及肠道不适发生率无统计学差异(P>0.05)。联合治疗组CD3^+,CD4^+及CD8^+细胞数均显著低于CAG组(P<0.05)。随访结果显示,联合治疗组2年累计总生存率为(76.2±6.3)%,显著高于CAG组(45.7±7.6)%(χ^2=4.214,P<0.05);联合治疗组2年累计无病生存率为(57.4±7.7)%,显著高于CAG组(30.3±7.9)%(χ^2=5.250,P<0.05)。结论:小剂量HAG及地西他滨联合方案治疗老年急性髓系白血病患者效果显著。

Efficacy of Small Dose HAG Regimen Combined with Decitabine in Treatment of Elderly Patients with Acute Myeloid Leukemia

Objective:To study the efficacy of small dose HAG combined with decitabine regimen in the treatment of elderly patients with acute myeloid leukemia(AML).Methods:134 elderly AML patients treated in our hospital from March 2015 to December 2018 were selected,and the patients were divided into CAG group and combined treatment group.The AML patients in CAG group was treated with CAG regimen,while the AML patients in combined treatment group was treated with small dose HAG regimen combined with decitabine.Efficacy was evaluated after treatment.Results:After treatment,the OR rate of the patients in combined treatment group was significantly higher than that in CAG group(χ^2=5.311,P=0.021).The nausea and vomiting rate,infection rate,myelosuppression rate,bleeding rate and intestinal discomfort rate showed no significant difference between the two groups(P>0.05).The CD3+,CD4+and CD8+levels of patients in combined treatment group were significantly lower than those in CAG group(P<0.05).The result of followed-up for 2 years,showed that the overall survival rate of patients in combined treatment group was significantly higher than that in CAG group[(76.2±6.3)%vs(45.7±7.6)%](χ^2=4.214,P<0.05),while the disease free survival rate of patients in combined treatment group were(57.4±7.7)%,which was significantly higher than that in CAG group(30.3±7.9)%(χ^2=5.250,P<0.05).Conclusion:Small dose HAG regimen combined with decitabine for elderly patients with acute myeloid leukemia has a certain curative efficacy.